Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia

BACKGROUND: NTZ is approved in Russia for the treatment of highly active relapsing remitting multiple sclerosis and is reimbursed via federal budget program. However, no data about NTZ treatment in Russia and the effect of federal reimbursement have been performed so far. OBJECTIVE: To characterize...

Descripción completa

Detalles Bibliográficos
Autores principales: Evdoshenko, Evgeniy, Stepanova, Alexandra, Shumilina, Maria, Davydovskaya, Maria, Khachanova, Natalia, Neofidov, Nikolay, Kalinin, Ivan, Popova, Ekaterina, Dubchenko, Ekaterina, Pozhidaeva, Natalia, Volkov, Andrey, Sivertseva, Stella, Prilenskaya, Anna, Malkova, Nadezhda, Korobko, Denis, Vergunova, Ilona, Shchur, Sergey, Makshakov, Gleb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538157/
https://www.ncbi.nlm.nih.gov/pubmed/31136608
http://dx.doi.org/10.1371/journal.pone.0217303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538157/
https://www.ncbi.nlm.nih.gov/pubmed/31136608
http://dx.doi.org/10.1371/journal.pone.0217303

Ejemplares similares